CLAIMS

1. Use of sodium DNA in the manufacture of a medicament for the treatment of the side effects of chlorhexidine in a patient undergoing chlorhexidine treatment, wherein such side effects entail an alteration of the cell structure of the oral mucosa of said patient, said alteration of the cell structure being selected in the group consisting of: vacuolisation, degeneration of the cell nucleus, expansion of intercellular spaces.

2. The use according to claim 1, in which said chlorhexidine treatment is made with an oral care product comprising chlorhexidine and sodium DNA.

3. The use according to claim 2, wherein said oral care product comprising chlorhexidine and sodium DNA is selected from the group consisting of: mouthwash, periodontal gel, and toothpaste.

4. The use according to claim 3, wherein said oral care product is a mouthwash and the amount of chlorhexidine is in the range from 0.01% to 0.30% by weight with respect to the total volume of the mouthwash.

5. The use according to 3 or 4, wherein said oral care product is a mouthwash and chlorhexidine is in the form of a salt or a complex.

6. The use according to any one of claims 3 to 5, wherein said oral care product is a mouthwash and the amount of sodium DNA is in the range from 0.01% to 0.2% by weight with respect to the total volume of the mouthwash.

7. The use according to anyone of claims 3 to 6, wherein said oral care product is a mouthwash comprising at least one metabisulfite salt of an alkaline or an alkaline earth metal.

8. The use according to anyone of claims 3 to 7, wherein said oral care product is a mouthwash comprising ascorbic acid.

9. The use according to anyone of claims 3 to 8, wherein said oral care product is a mouthwash comprising at least one polyvinylpyrrolidone-vinylacetate copolymer.

10. The use according to anyone of claims 3 to 9, wherein said oral care product is a mouthwash comprising sodium tribasic citrate.

11. The use according to anyone of claims 3 to 10, wherein said oral care product is a mouthwash comprising from 0.01% to 0.30% by weight of chlorhexidine, from 0.01% to 0.2% by weight of sodium DNA, from 0.1% to 0.5% by weight of at least one metabisulfite salt of an alkaline or an alkaline earth metal, from 0.1% to 1.0% by weight of ascorbic acid, from 0.05% to 1% by weight of at least one polyvinyl pyrrolidone-vinyl acetate copolymer, with respect to the total volume of the mouthwash.

12. The use according to claim 3, wherein said oral care product is a periodontal gel comprising from 0.5% to 1.0% by weight of chlorhexidine, with respect to the total volume of the periodontal gel.

13. The use according to 3 or 12, wherein said oral care product is a periodontal gel comprising sodium DNA in an amount at most of 0.3% by weight with respect to the total weight of the periodontal gel.

14. The use according to claim 3, wherein said oral care product is a toothpaste comprising from 0.05% to 0.2% by weight of chlorhexidine, with respect to the total volume of the toothpaste.

15. The use according to claim 3 or 14, wherein said oral care product is a toothpaste comprising sodium DNA in an amount from 0.01% to 0.05% by weight with respect to the total volume of the toothpaste.

16. The use according to any one of claims 1 to 15, wherein said chlorhexidine treatment is for the treatment of at least one pathology selected in the group consisting of: gingivitis, bacterial plaque, and periodontitis.